Pulmonary Disease, Chronic Obstructive
Conditions
Brief summary
To obtain further information on the tolerability of Atrovent® inhalets in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice
Interventions
Sponsors
Boehringer Ingelheim
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Primarily, Patients with chronic obstructive airways disease * Only patients who had not been treated with Atrovent® in the last year were to be considered for inclusion
Exclusion criteria
\- Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® inhalets
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Investigator assessment of improvement in the clinical picture of the course on a 6-point symptoms profile | Up to 4 weeks after first study drug administration |
Secondary
| Measure | Time frame |
|---|---|
| Investigator assessment of tolerability on a 4-point scale | Up to 4 weeks after first study drug administration |
| Number of patients with adverse drug reactions | Up to 4 weeks after first study drug administration |
| Number of patients who withdrew from the study | Up to 4 weeks after first study drug administration |
| Investigator assessment of efficacy on a 4-point scale | Up to 4 weeks after first study drug administration |
| Number of patients who continued the treatment | Up to 4 weeks after first study drug administration |
| Patient assessment of efficacy on a 4-point scale | Up to 4 weeks after first study drug administration |
| Patient assessment of tolerability on a 4-point scale | Up to 4 weeks after first study drug administration |
| Number of patients who changed the concomitant medication | Up to 4 weeks after first study drug administration |
Outcome results
None listed